As af Klint’s fame has grown, so have the questions—about what she believed, whom she worked with, and who should be allowed ...

Moderna's John Ward argues that the future of in-house trademark practice will belong to the teams that have the courage to ...

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies. Trump reverses on tariffs for some imports, Bitcoin falls on details of strategic reserve, ...

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 ...

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.